C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 24.2 PLN -0.62% Market Closed
Market Cap: 1.3B PLN

Intrinsic Value

The intrinsic value of one CLN stock under the Base Case scenario is 8.14 PLN. Compared to the current market price of 24.2 PLN, Celon Pharma SA is Overvalued by 66%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CLN Intrinsic Value
8.14 PLN
Overvaluation 66%
Intrinsic Value
Price
C
Base Case Scenario

Valuation History
Celon Pharma SA

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
CLN
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for CLN cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Celon Pharma SA
WSE:CLN
PL
Pharmaceuticals
Market Cap
1.2B PLN
IPO
Dec 1, 2016
PL
Pharmaceuticals
Market Cap
1.2B PLN
IPO
Dec 1, 2016
Price
złfalse
EPS
złfalse
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Celon Pharma SA
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Celon Pharma SA

Current Assets 193.3m
Cash & Short-Term Investments 103.3m
Receivables 55.1m
Other Current Assets 34.8m
Non-Current Assets 425.9m
Long-Term Investments 80.8m
PP&E 315.8m
Intangibles 10.2m
Other Non-Current Assets 19.1m
Efficiency

Free Cash Flow Analysis
Celon Pharma SA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Celon Pharma SA

Revenue
280.8m PLN
Cost of Revenue
-64.1m PLN
Gross Profit
216.7m PLN
Operating Expenses
-194.9m PLN
Operating Income
21.9m PLN
Other Expenses
-3.4m PLN
Net Income
18.5m PLN
Fundamental Scores

CLN Profitability Score
Profitability Due Diligence

Celon Pharma SA's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
ROE is Increasing
39/100
Profitability
Score

Celon Pharma SA's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

CLN Solvency Score
Solvency Due Diligence

Celon Pharma SA's solvency score is 84/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Negative Net Debt
Low D/E
84/100
Solvency
Score

Celon Pharma SA's solvency score is 84/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CLN Price Targets Summary
Celon Pharma SA

Wall Street analysts forecast CLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLN is 27.74 PLN with a low forecast of 15.66 PLN and a high forecast of 40.95 PLN.

Lowest
Price Target
15.66 PLN
35% Downside
Average
Price Target
27.74 PLN
15% Upside
Highest
Price Target
40.95 PLN
69% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for CLN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest
What is the Intrinsic Value of one CLN stock?

The intrinsic value of one CLN stock under the Base Case scenario is 8.14 PLN.

Is CLN stock undervalued or overvalued?

Compared to the current market price of 24.2 PLN, Celon Pharma SA is Overvalued by 66%.

Back to Top